Association of Chemokines and Chemokine Receptor Expression with Monocytic-Myeloid-Derived Suppressor Cells during Tumor Progression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells that show increased expression in cancer patients; however, the molecular mechanisms underlying their generation and function are unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer (BC), the presence and relevance of monocytic (Mo)-MDSCs are unknown. Here, we report for the first time increased chemokine and chemokine receptor production by Mo-MDSCs in BC patients. A clear population of Mo-MDSCs with the typical cell surface phenotype (human leukocyte antigen-antigen D related [HLA-DR]low/− CD11b+ CD33+ CD14+) increased significantly during disease progression. In addition, the chemokine receptor expression level on Mo-MDSCs in patients with invasive BC was the highest. Furthermore, different chemokine receptor expression patterns were noted in Mo-MDSCs between healthy controls (HC) and BC patients. Additionally, CD4 T cells proliferations were significantly decreased in the invasive BC groups compared with the HC group. However, the ductal carcinoma in situ (DCIS) group had no significantly compared with the HC group. Our data suggest that monitoring chemokine and chemokine receptor production by Mo-MDSCs may represent a novel and simple biomarker for assessing disease progression in BC patients.
Abstract
Myeloid-derived suppressor cells (MDSCs) are highly immunosuppressive myeloid cells that show increased expression in cancer patients; however, the molecular mechanisms underlying their generation and function are unclear. Whereas granulocytic-MDSCs correlate with poor overall survival in breast cancer (BC), the presence and relevance of monocytic (Mo)-MDSCs are unknown. Here, we report for the first time increased chemokine and chemokine receptor production by Mo-MDSCs in BC patients. A clear population of Mo-MDSCs with the typical cell surface phenotype (human leukocyte antigen-antigen D related [HLA-DR]low/− CD11b+ CD33+ CD14+) increased significantly during disease progression. In addition, the chemokine receptor expression level on Mo-MDSCs in patients with invasive BC was the highest. Furthermore, different chemokine receptor expression patterns were noted in Mo-MDSCs between healthy controls (HC) and BC patients. Additionally, CD4 T cells proliferations were significantly decreased in the invasive BC groups compared with the HC group. However, the ductal carcinoma in situ (DCIS) group had no significantly compared with the HC group. Our data suggest that monitoring chemokine and chemokine receptor production by Mo-MDSCs may represent a novel and simple biomarker for assessing disease progression in BC patients.
참고문헌 (35)
- Kusmartsev S, "Role of immature myeloid cells in mechanisms of immune evasion in cancer", Cancer Immunol Immunother, 55, pp.237~245 (2006)[DOI]
- Gabrilovich DI, "Myeloid-derived suppressor cells as regulators of the immune system", Nat Rev Immunol, 9, pp.162~174 (2009)[DOI]
- Vinay DS, "Immune evasion in cancer: mechanistic basis and therapeutic strategies", Semin Cancer Biol, 35(Suppl), pp.S185~S198 (2015)[DOI]
- Marcus A, "Recognition of tumors by the innate immune system and natural killer cells", Adv Immunol, 122, pp.91~128 (2014)
- Sato Y, "Characterization of the myeloid-derived suppressor cell subset regulated by NK cells in malignant lymphoma", OncoImmunology, 4, pp.e995541~ (2015)[DOI]
- Wesolowski R, "Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer", Cancer Immunol Immunother, 66, pp.1437~1447 (2017)[DOI]
- Toor SM, "Myeloid cells in circulation and tumor microenvironment of breast cancer patients", Cancer Immunol Immunother, 66, pp.753~764 (2017)[DOI]
- Khaled YS, "Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients", J Immunol Res, 2014, pp.879897~ (2014)
- Bronte V, "Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards", Nat Commun, 7, pp.12150~ (2016)[DOI]
- Albeituni SH, "Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer", Cancer J, 19, pp.490~501 (2013)[DOI]
- Brandau S, "Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties", J Leukoc Biol, 89, pp.311~317 (2011)[DOI]
- Wynn TA, "Myeloid-cell differentiation redefined in cancer", Nat Immunol, 14, pp.197~199 (2013)
- Zilio S, "Neutrophils and granulocytic MDSC: the Janus God of Cancer Immunotherapy", Vaccines (Basel), 4, pp.31~ (2016)[DOI]
- Zhao Y, "Phenotype, development, and biological function of myeloid-derived suppressor cells", OncoImmunology, 5, pp.e1004983~ (2015)
- Condamine T, "Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function", Trends Immunol, 32, pp.19~25 (2011)[DOI]
- Schlecker E, "Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth", J Immunol, 189, pp.5602~5611 (2012)[DOI]
- Sevko A, "Myeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thieves", J Cancer, 4, pp.3~11 (2013)[DOI]
- Meyer C, "Chronic inflammation promotes myeloid-derived suppressor cell activation blocking antitumor immunity in transgenic mouse melanoma model", Proc Natl Acad Sci U S A, 108, pp.17111~17116 (2011)[DOI]
- Chun E, "CCL2 promotes colorectal carcinogenesis by enhancing polymorphonuclear myeloid-derived suppressor cell population and function", Cell Reports, 12, pp.244~257 (2015)[DOI]
- Katoh H, "CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis", Cancer Cell, 24, pp.631~644 (2013)[DOI]
- Stromnes IM, "Molecular pathways: myeloid complicity in cancer", Clin Cancer Res, 20, pp.5157~5170 (2014)[DOI]
- Lebrun A, "<TEX>$CCR2^{+}$<", TEX> monocytic myeloid-derived suppressor cells (M-MDSCs) inhibit collagen degradation and promote lung fibrosis by producing transforming growth factor-<TEX>${\beta}1$<, J Pathol, pp.2017, 243[DOI]
- Alfaro C, "Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs)", Clin Cancer Res, 22, pp.3924~3936 (2016)[DOI]
- Qu P, "Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment", Cancer Lett, 380, pp.253~256 (2016)[DOI]
- Zhang B, "Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma", PLoS One, 8, pp.e57114~ (2013)[DOI]
- Khaled YS, "Myeloid-derived suppressor cells in cancer: recent progress and prospects", Immunol Cell Biol, 91, pp.493~502 (2013)[DOI]
- Highfill SL, "Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy", Sci Transl Med, 6, pp.237ra67~ (2014)[DOI]
- Ostrand-Rosenberg S, "Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression", Semin Cancer Biol, 22, pp.275~281 (2012)[DOI]
- O'Connor MA, "Subpopulations of M-MDSCs from mice infected by an immunodeficiency-causing retrovirus and their differential suppression of T- vs B-cell responses", Virology, 485, pp.263~273 (2015)[DOI]
- Finke J, "MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy", Int Immunopharmacol, 11, pp.856~861 (2011)[DOI]
- Yu J, "Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer", J Immunol, 190, pp.3783~3797 (2013)[DOI]
- Zhao W, "Subsets of myeloid-derived suppressor cells in hepatocellular carcinoma express chemokines and chemokine receptors differentially", Int Immunopharmacol, 26, pp.314~321 (2015)[DOI]
- Satomura H, "Can expression of CXCL12 and CXCR4 be used to predict survival of gastric cancer patients?", Anticancer Res, 34, pp.4051~4057 (2014)
- Ying J, "The expression of CXCL12 and CXCR4 in gastric cancer and their correlation to lymph node metastasis", Med Oncol, 29, pp.1716~1722 (2012)[DOI]
- Xiang Z, "A positive crosstalk between CXCR4 and CXCR2 promotes gastric cancer metastasis", Oncogene, 36, pp.5122~5133 (2017)[DOI]